Skip to content

Study · Not a test of the peptide alone · 2024

5 results

LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma.

Nielsen M, Monberg T, Sundvold V, Albieri B, Hovgaard D, Petersen MM, Krarup-Hansen A, Met Ö, Met Ö, Camilio K, Clancy T, Stratford R and 5 more

Show all authors

Sveinbjornsson B, Sveinbjornsson B, Rekdal Ø, Junker N, Svane IM

Oncoimmunology7 Dec 2023Cited by 36 (Europe PMC)

PMID38125722 (opens in a new tab)PMCIDPMC10732595 (opens in a new tab)DOI10.1080/2162402x.2023.2290900 (opens in a new tab)PepBankPUB-38125722
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking LTX-315.

  1. 01HumanNot a test of LTX-315 aloneNon-randomized trialSafety outcome

    In metastatic soft tissue sarcoma, the LTX‑315 and adoptive T-cell therapy regimen had only expected and manageable toxicity.

    In plain wordsIn sarcoma patients, the LTX‑315 and T-cell therapy regimen had expected and manageable toxicity.

    Peptide
    LTX-315
    Outcome
    Not applicableTreatment toxicity
    Study

    n = 6

    Outcome group
    Adverse events · Cancer

    Source sentences

    Summary
    Overall, the treatment was considered safe with only expected and manageable toxicity.
    2 context sentences
    Summary · context
    In the present pilot trial, we treated patients with metastatic soft tissue sarcoma with the combination of LTX-315 and adoptive T-cell therapy using in vitro expanded tumor-infiltrating lymphocytes.
    Summary · context
    Six heavily pretreated patients were included in the trial and treated with LTX-315 of which four patients proceeded to adoptive T-cell therapy.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  2. 02HumanNot a test of LTX-315 aloneNon-randomized trialMechanism

    In the sarcoma patient with stable disease, tumor-reactive blood T cells persisted until progression after the LTX‑315 and T-cell therapy regimen.

    In plain wordsIn one sarcoma patient, tumor-reactive blood T cells persisted until progression after the LTX‑315 and T-cell therapy regimen.

    Peptide
    LTX-315
    Outcome
    Not applicablePersistent circulating tumor-reactive T cells
    Study

    n = 1

    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    The best overall clinical response was stable disease for 208 days, and in this patient, we detected tumor-reactive T cells in the blood that lasted until disease progression.
    2 context sentences
    Summary · context
    In the present pilot trial, we treated patients with metastatic soft tissue sarcoma with the combination of LTX-315 and adoptive T-cell therapy using in vitro expanded tumor-infiltrating lymphocytes.
    Summary · context
    Six heavily pretreated patients were included in the trial and treated with LTX-315 of which four patients proceeded to adoptive T-cell therapy.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  3. 03HumanNot a test of LTX-315 aloneNon-randomized trialEfficacy outcome

    In metastatic soft tissue sarcoma, the best response to the LTX‑315 and T-cell therapy regimen was stable disease for 208 days.

    In plain wordsIn sarcoma patients, the best response to LTX‑315 and T-cell therapy was stable disease for 208 days.

    Peptide
    LTX-315
    Outcome
    Not applicableBest overall clinical response
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer

    Measurements

    Duration of stable disease (best overall clinical response)
    208 days
    best responder

    Source sentences

    Summary
    The best overall clinical response was stable disease for 208 days, and in this patient, we detected tumor-reactive T cells in the blood that lasted until disease progression.
    2 context sentences
    Summary · context
    In the present pilot trial, we treated patients with metastatic soft tissue sarcoma with the combination of LTX-315 and adoptive T-cell therapy using in vitro expanded tumor-infiltrating lymphocytes.
    Summary · context
    Six heavily pretreated patients were included in the trial and treated with LTX-315 of which four patients proceeded to adoptive T-cell therapy.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  4. 04HumanNot a test of LTX-315 aloneNon-randomized trialMechanism

    In three sarcoma patients receiving the LTX‑315 and T-cell therapy regimen, T-cell reactivity against predicted neoantigens was demonstrated.

    In plain wordsIn three sarcoma patients, T cells reacted to predicted tumor antigens after the LTX‑315 and T-cell therapy regimen.

    Peptide
    LTX-315
    Outcome
    Not applicableT-cell reactivity against predicted neoantigens
    Study

    n: not reported in source

    Outcome group
    Immune response · Cancer

    Measurements

    Patients with T-cell reactivity against predicted neoantigens
    3 patients
    LTX-315 and adoptive T-cell therapy

    Source sentences

    Summary
    In three patients T-cell reactivity against in silico predicted neoantigens was demonstrated.
    2 context sentences
    Summary · context
    In the present pilot trial, we treated patients with metastatic soft tissue sarcoma with the combination of LTX-315 and adoptive T-cell therapy using in vitro expanded tumor-infiltrating lymphocytes.
    Summary · context
    Six heavily pretreated patients were included in the trial and treated with LTX-315 of which four patients proceeded to adoptive T-cell therapy.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  5. 05HumanNot a test of LTX-315 aloneNon-randomized trialMechanism

    In patients with metastatic soft tissue sarcoma treated with LTX‑315 injections and adoptive T-cell therapy, new T-cell clones were generated and expanded in blood following the LTX‑315 injections.

    In plain wordsIn sarcoma patients given LTX‑315 and T-cell therapy, new T-cell clones appeared and expanded in blood after the LTX‑315 injections.

    Peptide
    LTX-315
    Outcome
    IncreaseDe novo circulating T-cell clones
    Study

    n: not reported in source

    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    Additionally, de novo T-cell clones were generated and expanded in the blood following LTX-315 injections.
    2 context sentences
    Summary · context
    In the present pilot trial, we treated patients with metastatic soft tissue sarcoma with the combination of LTX-315 and adoptive T-cell therapy using in vitro expanded tumor-infiltrating lymphocytes.
    Summary · context
    Six heavily pretreated patients were included in the trial and treated with LTX-315 of which four patients proceeded to adoptive T-cell therapy.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT03725605

LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04)

Lytix Biopharma ASn = 628 Dec 2018 to 11 Oct 2021

Soft Tissue Sarcoma

Trial pageClinicalTrials.govUpdated 5 Dec 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.